Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: The role of crizotinib

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 999-1007

  Niu, Fei Yu ^a,b   Wu, Yi Long ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

ALK; c Met; Crizotinib; NSCLC; ROS1

Indexed keywords

ALANINE AMINOTRANSFERASE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CERITINIB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; PEMETREXED; SCATTER FACTOR RECEPTOR; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CANCER RESISTANCE; CHINESE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINUS BRADYCARDIA; TREATMENT RESPONSE; VISUAL IMPAIRMENT; VOMITING;

EID: 84929394406     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S64664     Document Type: Article

References (75)

1. Tan W, Wilner KD, Bang Y, et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J Clin Oncol. 2010;28(suppl):abstr2596.
2. Kim D, Ahn M, Yang P, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Ann Oncol. 2012;23(suppl 9):ix402.
3. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394.
4. Solomon BJ, Mok T, Kim DW, et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
5. Pfizer. A Study of Crizotinib versus Chemotherapy in Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients; 2014. Available from: http://clinicaltrial.gov/ct2/show/NCT01639001. Accessed November 24, 2014. [NLM identifier: NCT01639001].
6. Cui JJ, Tran-Dubé M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54(18):6342–6363.
7. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12 pt 1):3314–3322.
8. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68(9):3389–3395.
9. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870.
10. Tan W, O’Gorman M, Lanzalone S, et al. Pharmacokinetics (PK) of crizotinib (PF-02341066), a dual ALK/C-MET inhibitor, following administration of multiple oral doses to patients with advanced ALK-positive NSCLC in China. J Thorac Oncol. 2012;7(suppl 5):S491.
11. Ou S-HI, Salgia R, Clark J, et al. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J Thorac Oncol. 2010;5(suppl 5):S382.
12. Li C, Alvey C, Bello A, Wilner KD, Tan W. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol. 2011;29(suppl):abstre13065.
13. Wang E, Nickens D, Bello A, Khosravan R, Amantea M, Tan W. Clinical implication of a population pharmacokinetic analysis of xalkori (crizotinib) in 1,182 patients with non-small cell lung cancer (NSCLC) and 32 patients with other solid tumors. J Thorac Oncol. 2013;8(suppl 2):S296.
14. Li Y, Li Y, Yang T, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One. 2013;8(1):e52093.
15. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010;9:188.
16. An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One. 2012;7(6):e40109.
17. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14(20):6618–6624.
18. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275–4283.
19. Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2013;31(suppl):abstr8000.
20. Zhang X, Lu S, Zhang L, et al. The Chinese expert consensus opinion of the diagnosis of ALK-positive NSCLC (2013 version). Chin J Pathol. 2013;42(6):402–406. [Chinese].
21. Ying J, Guo L, Qiu T, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013;24(10):2589–2593.
22. Demidova I, Barinov A, Savelov N, et al. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Arch Pathol Lab Med. 2014;138(6):794–802.
23. Wang J, Cai Y, Dong Y, et al. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. PLoS One. 2014;9(7):e101551.
24. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561–1571.
25. Minca EC, Portier BP, Wang Z, et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013;15(3):341–346.
26. Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014;9(5):631–638.
27. Guangdong Association of Clinical Trials. A Prospective Epidemiologic Study of ALK-Positive NSCLC in China (C-TALK); 2014. Available from: http://clinicaltrial.gov/ct2/show/NCT02042105. Accessed November 24, 2014. [NLM identifier: NCT02042105].
28. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med. 2012;136(7):796–803.
29. Li Y, Pan Y, Wang R, et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One. 2013;8(7):e69016.
30. Wu YC, Chang IC, Wang CL, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One. 2013;8(8):e70839.
31. Zhang YG, Jin ML, Li L, et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT-PCR on paraffin-embedded tissues. PLoS One. 2013;8(5):e64821.
32. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–1019.
33. Shaw AT, Yeap BY, Solomon BJ, et al. Overall survival in patients with advanced non-small cell lung cancer harboring concomitant EGFR mutations and ALK rearrangements: A cohort study. J Clin Oncol. 2014;32(suppl):abstre19010.
34. Cheng Y, Zhu J. Clinical characteristics of ALK-positive advanced NSCLC patients and the clinical study of crizotinib 2014. Oral presented at: The Chinese Society of Clinical Oncology; September 17–21; 2013; Xiamen. [Chinese].
35. Loren CE, Englund C, Grabbe C, Hallberg B, Hunter T, Palmer RH. A crucial role for the anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. EMBO Rep. 2003;4(8):781–786.
36. Bazigou E, Apitz H, Johansson J, et al. Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila. Cell. 2007;128(5):961–975.
37. Blackhall F, Shaw A, Jänne P, et al. Crizotinib safety profile in elderly and non-elderly patients with advanced ALK+ non-small cell lung cancer. Poster presented at: The European Cancer Congress; September 27; 2013; Amsterdam.
38. Frampton JE. Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): profile 1005. J Thorac Oncol. 2011;6(suppl 2):S411.
39. Ou S-HI, Kim D-W, Camidge DR, et al. Crizotinib therapy for patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). J Thorac Oncol. 2013;8(suppl 2):S295.
40. Cao Y, Xiao G, Qiu X, Ye S, Lin T. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(suppl):abstr8001.
41. Schnell P, Safferman AZ, Bartlett CH, Tang Y, Wilner KD. Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK+) advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30(suppl):abstr7598.
42. Hida T, Shi Y, Ahn M-J, et al. Exploratory subgroup analysis of crizotinib efficacy and safety in Asian and non-Asian patients with advanced ALK-positive non-small cell lung cancer (NSCLC) enrolled in a global phase II study. J Thorac Oncol. 2012;7(suppl):5.
43. Ou S-HI, Tang Y, Polli A, Wilner KD, Schnell P. Characterization of heart rate (HR) changes during crizotinib treatment: a retrospective analysis of 1,053 ALK+ NSCLC patients. J Clin Oncol. 2014;32(suppl):abstre13065.
44. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472–1482.
45. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra117.
46. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–1197.
47. Nakagawa K, Hida T, Seto T, et al. Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. J Clin Oncol. 2014;32(suppl):abstr8103.
48. Gettinger SN, Bazhenova L, Salgia R, et al. Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(suppl):abstr8047.
49. Ou SH, Jänne PA, Bartlett CH, et al. Clinical benefit of continuing crizotinib beyond initial disease progression in patients with advanced ALK-positive non-small cell lung cancer. J Thorac Oncol. 2013;8(suppl 2):S294.
50. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–1284.
51. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;59(12):2776–2780.
52. De Paepe P, Baens M, van Krieken H, et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood. 2003;102(7):2638–2641.
53. Jazii FR, Najafi Z, Malekzadeh R, et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol. 2006;12(44):7104–7112.
54. Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol. 2011;24(3):430–442.
55. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009;7(9):1466–1476.
56. Mano H. ALKoma: A cancer subtype with a shared target. Cancer Discov. 2012;2(6):495–502.
57. Butrynski JE, D’Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363(18):1727–1733.
58. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364(8):775–776.
59. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–1203.
60. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: Identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18(16):4449–4457.
61. Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014;84(2):121–126.
62. Clavé S, Gimeno J, De Muga S, et al. ROS1 rearrangements and copy number alterations in NSCLC patients: High frequency of ROS1 deletions. Ann Oncol. 2014;25(suppl 4):iv566.
63. Go H, Kim DW, Kim D, et al. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol. 2013;8(11):1445–1450.
64. Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, et al. Detection of ROS1 translocations in triple-negative lung adenocarcinomas. J Clin Oncol. 2013;31(suppl):abstr8099.
65. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
66. Li A, Yang J, Zhang X, Zhou Q, Wu Y. Targeting de novo cMET overexpression in advanced non-small cell lung cancer. Ann Oncol. 2014;25(suppl 4):iv68.
67. Li A, Gao HF, Wu YL. Targeting the MET pathway for potential treatment of NSCLC. Expert Opin Ther Targets. 2014;23:1–12.
68. Lou NN, Yang J, Zhang X, Chen H, Wu Y. De novo MET overexpression coexisting with oncogenic drivers in advanced non-small cell lung cancer. Ann Oncol. 2014;25(suppl 4):iv462.
69. Yang JJ, Zhang XC, Su J, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: Diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res. 2014;20(5):1383–1392.
70. Yamaguchi N, Lucena-Araujo AR, Nakayama S, et al. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer. 2014;83(1):37–43.
71. Yang JJ, Chen HJ, Yan HH, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer. 2013;79(1):33–39.
72. Landi L, Minuti G, D’Incecco A, Cappuzzo F. MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs. J Clin Oncol. 2014;32(suppl):abstract 19047.
73. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–1043.
74. Janne PA, Shaw AT, Giaccone G, et al. Phase I trial of irreversible pan-ERBB inhibitor dacomitinib (DAC) in combination with ALK/MET inhibitor crizotinib (CRIZ) in previously treated advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2012;23(suppl 9):ix423.
75. Gou L, Wu Y, Yang J, Zhang X. Targeting c-MET overexpression for acquired resistance to EGFR TKIs. Ann Oncol. 2014;25(suppl 4):iv450.